COX 2: Squeezing Blood Into Cancers

Roy, Hemant K.; Thompson, Jon S.
November 2000
American Journal of Gastroenterology;Nov2000, Vol. 95 Issue 11, p3032
Academic Journal
Discusses research being done on the modulation of carcinoma growth with the use of host cyclooxygenase-2. Reference to a study by C. S. Williams et al., published in a 2000 issue of the "Journal of Clinical Investigation"; Biological importance of the cyclooxygenase (COX) 2 overexpression; Results of the treatment with the COX 2 inhibitor celecoxib.


Related Articles

  • Preventive but Not Curative Efficacy of Celecoxib on Bladder Carcinogenesis in a Rat Model. Sereno, José; Parada, Belmiro; Reis, Flávio; Cunha, Fernanda X.; Teixeira-Lemos, Edite; Garrido, Patrícia; Pinto, Rui; Rocha-Pereira, Petronila; Neto, Paula; Ruivo, José; Rodrigues-Santos, Paulo; Nunes, Sara; Mota, Alfredo; Figueiredo, Arnaldo; Teixeira, Frederico // Mediators of Inflammation;2010, Vol. 2010, p1 

    To evaluate the effect of a cyclooxygenase 2 inhibitor, celecoxib (CEL), on bladder cancer inhibition in a rat model, when used as preventive versus as curative treatment. The study comprised 52 male Wistar rats, divided in 5 groups, during a 20-week protocol: control: vehicle, carcinogen: 0.05%...

  • A low carbohydrate, high protein diet combined with celecoxib markedly reduces metastasis. Ho, Victor W.; Hamilton, Melisa J.; Dang, Ngoc-Ha Thi; Hsu, Brian E.; Adomat, Hans H.; Guns, Emma S.; Weljie, Aalim; Samudio, Ismael; Bennewith, Kevin L.; Krystal, Gerald // Carcinogenesis;Oct2014, Vol. 35 Issue 10, p2291 

    We show herein using both a short-term breast cancer (4T1) and long-term prostate cancer (Transgenic Adenocarcinoma of the Mouse Prostate) mouse model that a combination of a low carbohydrate, high protein diet with celecoxib substantially reduces metastasis.We recently demonstrated that both...

  • The Potential and Rationale for COX-2 Inhibitors in Lung Cancer. Krysan, Kostyantyn; Reckamp, Karen L.; Sharma, Sherven; Dubinett, Steven M. // Anti-Cancer Agents in Medicinal Chemistry;2006, Vol. 6 Issue 3, p209 

    Cyclooxygenase-2 (COX-2) overexpression is seen in many malignancies including lung cancer. Elevated tumor prostaglandin E2 (PGE2), a major COX-2 metabolite, levels have been implicated in angiogenesis, tumor growth and invasion, apoptosis resistance and suppression of anti-tumor immunity....

  • In Vivo Optical Molecular Imaging of Matrix Metalloproteinase Activity following Celecoxib Therapy for Colorectal Cancer. Sheth, Rahul A.; Kunin, Alexandra; Stangenberg, Lars; Sinnamon, Mark; Hung, Kenneth E.; Kucherlapati, Raju; Mahmood, Umar // Molecular Imaging;Sep/Oct2012, Vol. 11 Issue 5, p417 

    We present an optical molecular imaging approach to measure the efficacy of the cyclooxygenase-2 (COX-2) inhibitor celecoxib on tumor growth rate through its effect on matrix metalloproteinase (MMP) activity. A xenograft model of colorectal cancer was generated in nude mice, which were then...

  • Phase II nonrandomized study of the efficacy and safety of COX-2 inhibitor celecoxib on patients with cancer cachexia. Mantovani, Giovanni; Macciò, Antonio; Madeddu, Clelia; Serpe, Roberto; Antoni, Giorgia; Massa, Elena; Dessì, Mariele; Panzone, Filomena // Journal of Molecular Medicine;Jan2010, Vol. 88 Issue 1, p85 

    Chronic inflammation is one of the main features of cancer cachexia. Experimental and clinical studies showed that cyclooxygenase-2 inhibitors, such as celecoxib, may be beneficial in counteracting major symptoms of this devastating syndrome. We carried out a prospective phase II clinical trial...

  • Celecoxib reduced risk for new colorectal adenomas after drug cessation.  // Hem/Onc Today;6/25/2008, Vol. 9 Issue 11, p20 

    The article reports that the chemopreventive effects of celecoxib is observed to persist for two years after the end of treatment. Celecoxib, a cyclooxygenase (COX)-2 inhibitor, has demonstrated chemopreventive effects, but with undetermined safety, according Nadir Arber, a professor at the...

  • A phase I trial of celecoxib in combination with docetaxel and irinotecan in patients with advanced cancer. Dy, Grace K.; Mandrekar, Sumithra; Peethambaram, Prema P.; Okuno, Scott H.; Croghan, Gary C.; Hanson, Lorelei J.; Furth, Alfred; Adjei, Alex A. // Cancer Chemotherapy & Pharmacology;Dec2005, Vol. 56 Issue 6, p623 

    Purpose: This phase I study was conducted to determine the safety, tolerability and maximum tolerated dose of the combination of celecoxib, a selective cyclooxygenase-2 inhibitor, with docetaxel and irinotecan, in patients with advanced solid tumors.Patients and Methods:...

  • Celecoxib inhibits growth of tumors in a syngeneic rat liver metastases model for colorectal cancer. de Heer, Pieter; Sandel, Maro H.; Guertens, Gunther; de Boeck, Gert; Koudijs, Margaretha M.; Nagelkerke, J. Fred; Junggeburt, Jan M. C.; de Bruijn, Ernst A.; van deVelde, Cornelis J. H.; Kuppen, Peter J. K. // Cancer Chemotherapy & Pharmacology;Oct2008, Vol. 62 Issue 5, p811 

    Nonsteroidal anti-inflammatory drugs (NSAIDs) have been shown to reduce the risk of colorectal cancer in cyclooxygenase-2 (COX-2) overexpressing colorectal cancers. The present study was designed to evaluate the inhibitory effects of the COX-2 inhibitor celecoxib on the growth of colorectal...

  • Importance of the EP1 Receptor in Cutaneous UVB-Induced Inflammation and Tumor Development. Tober, Kathleen L.; Wilgus, Traci A.; Kusewitt, Donna F.; Thomas-Ahner, Jennifer M.; Maruyama, Takayuki; Oberyszyn, Tatiana M. // Journal of Investigative Dermatology;Jan2006, Vol. 126 Issue 1, p205 

    Chronic exposure to UV light, the primary cause of skin cancer, results in the induction of high levels of cyclooxygenase-2 (COX-2) expression in the skin. The involvement of COX-2 in the carcinogenesis process is mediated by its enzymatic product, prostaglandin E2 (PGE2). PGE2 has been shown to...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics